ANAPC16 activators encompass a diverse group of molecules that interact with cellular mechanisms to modulate the activity of C10orf104, a component within the anaphase-promoting complex/cyclosome (APC/C). The anaphase-promoting complex is a pivotal E3 ubiquitin ligase that orchestrates the progression of cells through mitosis by targeting specific cell cycle regulators for proteasomal degradation. Molecules classified under this chemical class engage with various proteins and enzymes that are upstream regulators or direct modulators of the APC/C, resulting in an influence on C10orf104 activity. These activators operate through a variety of mechanisms, such as inhibiting the enzymes responsible for the ubiquitination and subsequent degradation of APC/C inhibitors or altering the phosphorylation state of APC/C components, which can have an impact on the assembly and functional competence of the complex.
The modulation of C10orf104 by these activators is understood to be an indirect consequence of their primary interactions with other cellular targets. For instance, some molecules in this class are known to inhibit kinases that phosphorylate APC/C, leading to changes in the complex's activity. Others may bind to regulatory subunits of the APC/C, competing with natural substrates and thus influencing the availability and activity of C10orf104 within the complex. Furthermore, certain molecules can affect the stability of proteins that interact with APC/C, altering the degradation pathway and possibly resulting in altered C10orf104 activity. The exact outcome of such interactions depends on the specific molecular context within the cell, the concentration of the activator, and the presence of other regulatory factors. Collectively, these molecules provide insight into the intricate regulatory networks that govern cell cycle progression and the sophisticated control mechanisms that are essential for maintaining cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits NEDD8-activating enzyme, preventing neddylation that modulates APC/C activity; this could possibly activate ANAPC16 upon drug removal. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
BI 2536 inhibits PLK1, a kinase that can phosphorylate APC/C components, potentially leading to changes in APC/C activity; this could possibly activate ANAPC16. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can cause accumulation of APC/C substrates, which could possibly activate ANAPC16. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine inhibits CDKs, which can decrease phosphorylation of APC/C components, potentially affecting APC/C activity; this could possibly activate ANAPC16. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM447439 inhibits Aurora kinases, which may impact APC/C activity by modifying the phosphorylation of APC/C components; this could possibly activate ANAPC16. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Tozasertib is a pan-Aurora kinase inhibitor, which could affect the activity of the APC/C complex by altering kinase activity; this could possibly activate ANAPC16. | ||||||
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $66.00 $163.00 $326.00 | 37 | |
RO-3306 inhibits CDK1, affecting the activation state of APC/C by modulating the cell cycle and APC/C phosphorylation state; this could possibly activate ANAPC16. | ||||||